| アブストラクト | Diarrhoea is an adverse drug reaction of the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril + valsartan. It was also described with olmesartan and more recently with other angiotensin receptor blockers. The study was performed to compare diarrhoea reports in pharmacovigilance databases with sacubitril + valsartan and valsartan. The study used reports of diarrhoea with the ARNI sacubitril + valsartan registered: first in the French PharmacoVigilance Database (FPVD) and second in Vigibase(R), the WHO Global Individual Case Safety Report database. After description of the main characteristics, disproportionality analyses were performed. Results are reported as reporting odds ratios (ROR) with 95% confidence interval. We found 29 reports of diarrhoea with sacubitril + valsartan in the FPVD and 686 in Vigibase(R). With sacubitril + valsartan, diarrhoea occurred more frequently in males around 70 years with a median delay of 3 days. With valsartan, diarrhoea occurred more frequently in females around 68 years with a median delay of 0.5 days. In the FPVD, a significant association was found with sacubitril + valsartan in comparison with valsartan alone before (ROR = 8.78 [5.19-14.85]) and after (ROR = 11.19 [5.89-21.25]) exclusion of concomitant drugs known to be associated with diarrhoea. A significant association was also found in Vigibase(R) after adjustment on age, sex, reporter and its location (ROR = 1.31 [1.14-1.50]). Diarrhoea reported with sacubitril + valsartan has marked differences in gender, delay of occurrence and frequency of reporting in comparison with diarrhoea with valsartan. From a pharmacodynamic point of view, these results suggest a specific role of sacubitril in diarrhoea. |
|---|
| ジャーナル名 | Fundamental & clinical pharmacology |
|---|
| 投稿日 | 2021/7/15 |
|---|
| 投稿者 | Guion-Firmin, Julia; Tessier, Samuel; Lepelley, Marion; Faillie, Jean-Luc; Montastruc, Jean-Louis |
|---|
| 組織名 | Service de Pharmacologie Medicale et Clinique, Centre de Pharmacovigilance de;Pharmacoepidemiologie et d'Informations sur le Medicament, CIC INSERM 1436,;Centre Hospitalier Universitaire-Faculte de Medecine, Toulouse, France.;Centre de Pharmacovigilance, Centre Hospitalier Universitaire, Universite de;Grenoble, Grenoble, France.;Montpellier, Montpellier, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34260768/ |
|---|
